Biotech News

Altimmune to Participate in the 9th Annual Evercore Healthcare Conference

Altimmune (ALT)AltimmuneConference / presentation

Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, in serious liver diseases, today announced that management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, at 3:25 p.m. ET.

Related news

Altimmune

Metabolic and Liver Disease Company Altimmune develops pemvidutide for serious metabolic and liver diseases. Balanced Dual Agonist Pemvidutide is a balanced glucagon and GLP-1 receptor agonist intended to combine weight loss with direct effects on liver fat, inflammation, and lipid metabolism. MASH Program The global PERFORMA program is...

Recent company news

Stock data

Close
1.41 USD
Market cap
563.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States